Ultragenyx wins FDA nod for first Sanfilippo drug
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc. (RARE) announced that the U.S. Food and Drug Administration granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for treating pediatric patients with mucopolysaccharidosis type IIIA (Sanfilippo syndrome Type A).
FAYUVI is described as the first FDA-approved treatment for this progressive and fatal neurodegenerative disease and the second gene therapy approval for Ultragenyx. The company also received a Priority Review Voucher in connection with this approval.
Positive
- Full FDA approval of FAYUVI (UX111) for pediatric MPS IIIA (Sanfilippo Type A), the first approved treatment for this disease and Ultragenyx’s second gene therapy approval, strengthens the company’s rare-disease portfolio.
- Ultragenyx received a Priority Review Voucher with this approval, a potentially valuable regulatory asset that can accelerate review of a future product or be sold to another company.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
FDA approval date: September 17, 2026
Gene therapy approvals for Ultragenyx: 2 approvals
Priority Review Voucher: 1 voucher
3 metrics
FDA approval date
September 17, 2026
Date Ultragenyx reported standard full approval of FAYUVI
Gene therapy approvals for Ultragenyx
2 approvals
FAYUVI is described as the company’s second gene therapy approval
Priority Review Voucher
1 voucher
Ultragenyx received a Priority Review Voucher upon FAYUVI approval
Key Terms
mucopolysaccharidosis type IIIA, Sanfilippo syndrome Type A, gene therapy, Priority Review Voucher, +1 more
5 terms
mucopolysaccharidosis type IIIA medical
"for the treatment of pediatric patients with mucopolysaccharidosis type IIIA"
Sanfilippo syndrome Type A medical
"MPS IIIA, Sanfilippo syndrome Type A, a progressive and fatal"
A severe inherited childhood disease caused by lack of an enzyme needed to break down certain sugars, leading to toxic buildup that destroys brain and body tissue over time. Imagine a household trash system that stops working and garbage piles up, eventually overwhelming the home; similarly, cells are damaged leading to developmental decline and shortened lifespan. For investors, it matters because drug research, clinical trials, and potential therapies for this rare condition can drive biotech valuation, regulatory milestones, and partnerships.
gene therapy medical
"the second gene therapy approval for Ultragenyx"
Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.
Priority Review Voucher regulatory
"The Company received a Priority Review Voucher upon this approval"
A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.
standard full approval regulatory
"the FDA granted standard full approval of FAYUVI"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ultragenyx (RARE) announce regarding FAYUVI (UX111)?
Ultragenyx announced that the FDA granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for treating pediatric patients with mucopolysaccharidosis type IIIA (Sanfilippo syndrome Type A), a progressive and fatal neurodegenerative disease.
For which condition is FAYUVI now approved according to Ultragenyx’s 8-K?
FAYUVI is approved to treat pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A), which is characterized as a progressive and fatal neurodegenerative disease.
What is the regulatory significance of FAYUVI for Ultragenyx (RARE)?
FAYUVI is described as the first-ever FDA-approved treatment for Sanfilippo syndrome Type A and represents the second gene therapy approval for Ultragenyx, marking continued progress in its gene therapy pipeline.
Did Ultragenyx receive any additional benefits with FAYUVI’s FDA approval?
Yes. Ultragenyx states it received a Priority Review Voucher upon FDA approval of FAYUVI. Such vouchers can be used to obtain priority review for another product application or can be transferred to another company.
When did Ultragenyx report the FDA approval of FAYUVI?
Ultragenyx reported the FDA approval of FAYUVI on September 17, 2026, as indicated by the dated signature block of the company’s Executive Vice President and Chief Financial Officer, Howard Horn.
AI-generated analysis. How Rhea-AI works. Not financial advice.
